A new form of immunotherapy has shown promising results in targeting and combating one of the most aggressive skin cancer, melanoma.
Researchers from Guy's and St Thomas' NHS Foundation Trust and King's College, London, developed a specific immunoglobulin (Ig)E antibody for chondroitin sulfate proteoglycan 4 (CSPG4) – a marker found on up to 70% of melanomas. The study found that the CSPG4 IgE antibody could attach to and activate immune cells to kill melanoma cancer cells and inhibit cancer growth in mice. This new class of drugs could potentially benefit patients who do not respond to current therapies and paves the way for a new therapeutic modality for fighting cancer.
Please login to comment on this article